Literature DB >> 17206414

Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?

Sandip Basu, Abass Alavi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17206414     DOI： 10.1007/s00259-006-0315-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  13 in total

1.  Imaging features of primary and recurrent esophageal cancer at FDG PET.

Authors:  S J Skehan; A L Brown; M Thompson; J E Young; G Coates; C Nahmias
Journal:  Radiographics       Date:  2000 May-Jun       Impact factor: 5.333

Review 2.  Esophageal cancer.

Authors:  Peter C Enzinger; Robert J Mayer
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

3.  Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer.

Authors:  Cuong P Duong; Helen Demitriou; Leann Weih; Anne Thompson; David Williams; Robert J S Thomas; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-10       Impact factor: 9.236

4.  Survival after surgery for oesophageal cancer: a population-based study.

Authors:  Ioannis Rouvelas; Wenyi Zeng; Mats Lindblad; Pernilla Viklund; Weimin Ye; Jesper Lagergren
Journal:  Lancet Oncol       Date:  2005-11       Impact factor: 41.316

5.  The additional value of PET/CT over PET in FDG imaging of oesophageal cancer.

Authors:  Rachel Bar-Shalom; Ludmila Guralnik; Medy Tsalic; Max Leiderman; Alex Frenkel; Diana Gaitini; Alon Ben-Nun; Zohar Keidar; Ora Israel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04-19       Impact factor: 9.236

6.  Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.

Authors:  P Flamen; A Lerut; E Van Cutsem; W De Wever; M Peeters; S Stroobants; P Dupont; G Bormans; M Hiele; P De Leyn; D Van Raemdonck; W Coosemans; N Ectors; K Haustermans; L Mortelmans
Journal:  J Clin Oncol       Date:  2000-09-15       Impact factor: 44.544

7.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

Authors:  Bryan H Burmeister; B Mark Smithers; Val Gebski; Lara Fitzgerald; R John Simes; Peter Devitt; Stephen Ackland; David C Gotley; David Joseph; Jeremy Millar; John North; Euan T Walpole; James W Denham
Journal:  Lancet Oncol       Date:  2005-09       Impact factor: 41.316

8.  Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?

Authors:  Olga Vrieze; Karin Haustermans; Walter De Wever; Toni Lerut; Eric Van Cutsem; Nadine Ectors; Martin Hiele; Patrick Flamen
Journal:  Radiother Oncol       Date:  2004-12       Impact factor: 6.280

9.  A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer.

Authors:  Trevor Leong; Craig Everitt; Kally Yuen; Sara Condron; Andrew Hui; Samuel Y K Ngan; Alexander Pitman; Eddie W F Lau; Michael MacManus; David Binns; Trevor Ackerly; Rodney J Hicks
Journal:  Radiother Oncol       Date:  2006-03-20       Impact factor: 6.280

10.  FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer.

Authors:  Cuong P Duong; Rodney J Hicks; Leann Weih; Elizabeth Drummond; Trevor Leong; Michael Michael; Robert J S Thomas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-21       Impact factor: 9.236
View more
  2 in total

Review 1.  Personalized versus evidence-based medicine with PET-based imaging.

Authors:  Sandip Basu
Journal:  Nat Rev Clin Oncol       Date:  2010-08-10       Impact factor: 66.675

2.  Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer.

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.